BioVaxys Technology Corp.

As of April 30, 2025, BioVaxys Technology Corp. has 29.15M shares outstanding.

These figures are as of April 30, 2025.

As of April 30, 2025, BioVaxys Technology Corp. maintains a current ratio of 0.29, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended April 30, 2025. Return on assets (ROA) is negative at -440.76, reflecting losses generated across the asset base.

As of the close on June 1, 2026, BioVaxys Technology Corp.'s stock has gained approximately 133.33% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.16.

These figures cover the twelve months ended April 30, 2025. Free cash flow yield is negative at -302.18: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -368.99, meaning BioVaxys Technology Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

BioVaxys Technology Corp.'s most recent stock split took place on September 11, 2025 with a 10:1 split ratio.

As of April 30, 2025, BioVaxys Technology Corp. has an Altman Z-Score of -60.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.